-
Dr. Adi Hoess to step down as CEO and Management Board Member
-
Dr. Andreas Harstrick appointed Interim CEO
-
Strategic restructuring reducing headcount by up to 50%, extending cash runway into H2 2025
-
Go forward organization will focus on advancing clinical programs
-
Company confirms guidance on data readouts for AFM24-102 and LuminICE-203 in H1 2024
MANNHEIM, Germany, Jan. 08, 2024 (GLOBE NEWSWIRE) — Affimed N.V. (Nasdaq: AFMD) (the “Company” or “Affimed”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that Dr. Adi Hoess, Chief Executive Officer and member of the Management Board, will step down effective January 15, 2024. …
Read the full article at: https://uk.finance.yahoo.com/news/affimed-announces-leadership-change-organizational-130000837.html